Intravenous Immunoglobulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Efficacy of Intravenous Immunoglobulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1061220010

Enrollment

Registered

2022-04-25

Start date

2022-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

5 g/day of intravenous human immunoglobulin for 3 consecutive days.

D016756

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with acute exacerbation of IPF (2) Patients whose consent for participation in this study can be obtained personally or through his/her legal representative (3) Patients who are 20 years old or older at the time of obtaining consent.

Exclusion criteria

Exclusion criteria: (1) Patients considered to have acute exacerbation of interstitial pneumonia other than IPF (IIPs other than IPF, collagen vascular disease-associated ILD, etc.) (2) Patients who cannot give consent for the use of blood products (3) Patients who are denied the coexistence of infectious diseases and do not receive antibiotics (4) Patients who have a history of acute exacerbation of IPF (5) Patients judged unsuitable to participate in this clinical study by the investigator

Design outcomes

Primary

Measure	Time frame
survival proportion on day 90 (confirmed cases by central review)	—

Secondary

Measure	Time frame
(1) Identification of prognostic factors (2) safety (3) survival proportion on day 90 (all cases)	—

Contacts

Public ContactHisao Higo

Okayama University Hospital

hhigo@okayama-u.ac.jp+81-86-235-7227

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026